NGLFINE vs SUPRIYA: Stock Comparison

NGL Fine-Chem Limited vs Supriya Lifescience Limited

Live data: 22 July 2026, 3:05 PM IST • Source: NSE and company filings

Supriya Lifescience Limited is the larger company by market capitalisation. NGL Fine-Chem Limited shows faster revenue growth, while Supriya Lifescience Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of NGL Fine-Chem Limited and Supriya Lifescience Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NGLFINE is more favourable on 5 of 13 scored metrics and SUPRIYA on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SUPRIYA is the larger company
₹6,754 Cr vs ₹2,015 Cr
P/E Ratio
SUPRIYA has a lower P/E
33.24x vs 41.23x
P/B Ratio
SUPRIYA has a lower P/B
5.8x vs 6.03x
EPS
NGLFINE has higher earnings per share
₹78.04 vs ₹25.94
Dividend Yield
SUPRIYA has a higher dividend yield
0.11% vs 0.05%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs 50.2%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs 46.7%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
57.1% vs 50.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNGLFINESUPRIYA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNGLFINESUPRIYA
Live Price₹3,260₹839.9
Day Change0.7%-2.74%
Volume5,5951.78 L
52-Week High₹3,329₹1,085
52-Week Low₹1,175.5₹545.5
Distance from 52W High-2.07%-22.59%

Valuation

MetricNGLFINESUPRIYA
Market Cap₹2,015 Cr₹6,754 Cr
P/E Ratio41.23x33.24x
P/B Ratio6.03x5.8x
EPS₹78.04₹25.94
Book Value₹532.95₹148.77
Dividend Yield0.05%0.11%

Growth

MetricNGLFINESUPRIYA
Revenue Growth (TTM YoY)57.2%50.2%
EPS Growth (TTM YoY)1,539.8%46.7%
Qtr Sales Growth57.1%50.2%
Qtr Profit Growth2,398%47.3%

Profitability & Leverage

MetricNGLFINESUPRIYA
ROE15.7%19.1%
ROCE17%25.1%
Net Margin9.59%25.26%
Operating Margin14.5%35.5%
Debt to Equity0.33x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricNGLFINESUPRIYA
Promoter Holding72.74%68.3%
FII Holding0.03% 0.03 pp5.16% 0.04 pp
DII Holding0%5.7% 0.69 pp
Public Holding27.24% 0.02 pp20.84% 0.66 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NGL Fine-Chem Limited and Supriya Lifescience Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.